Nektar Therapeutics Azioni (NASDAQ: NKTR)

Ultime notizie per Nektar Therapeutics (NASDAQ:NKTR) Azioni

Nektar Therapeutics

Nektar Therapeutics is a pharmaceutical company focused on the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It is focused on discovering and developing medicines in the field of immunotherapy. Nektar's clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases (e.g. rezpegaldesleukin and NKTR-0165, respectively) and cancer (e.g. NKTR-255).

NEKTAR THERAPEUTICS ORD

– Relapse-free/progression-free survival for NKTR-255 plus CD19-22&nbsp;CAR-T cell therapy at 12 months was double that of historical controls (67% vs 38%) –
– Eight of nine patients achieved complete remission, all without detectable MRD –
SAN FRANCISCO, Oct. 17, 2024 /PRNewswire/ --&nbsp;Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) today announced the publication of the first clinical data from a Phase 1 study evaluating NKTR-255 in combination with an autologous bispecific chimeric antigen receptor (CAR)-T cell therapy targeting CD19 and CD22 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) in Blood, the peer-reviewed medical journal of the American Society of Hematology.
NKTR-255 is a novel IL-15 receptor agonist currently being studied in clinical trials in combination with cellular therapies and immune checkpoint inhibitors. NKTR-255 has shown in previous clinical studies that it can proliferate a range of immune cells and augment lymphocyte trafficking.1,2
The data published in Blood showed favorable efficacy with eight out of nine patients (89%) whom successfully received CAR19-22 followed by NKTR-255 achieving measurable residual disease (MRD) negative remission. The study further demonstrated that, at 12 months, relapse-free/progression-free survival for NKTR-255 in combination with the CD19-22 CAR-T cell therapy was double that of historical controls (67% vs 38%).

Biotech

News

General

NKTR

Nektar Announces Publication In Blood Of Phase 1 Data For Novel IL-15 Agonist NKTR-255 In Combination With Autologous CD19-22 CAR-T Cell Therapy In Patients With B-cell Acute Lymphoblastic Leukemia

BTIG analyst Robert Hazlett assumes Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) with a Buy rating and announces Price Target of $4.

Price Target

Initiation

Analyst Ratings

BTIG Assumes Nektar Therapeutics at Buy, Announces Price Target of $4

Nektar Therapeutics Announced Several Presentations For Rezpegaldesleukin At The 2024 European Academy Of Dermatology And Venereology Congress

Nektar Therapeutics (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nktr#NASDAQ">NKTR</a>) incurred a loss per share of 25 cents in the second quarter of 2024, which was wider than the Zacks Consensus Estimate of a loss of 21 cents.
Excluding the impact of non-cash restructuring and impairment charges, the company reported an adjusted loss of 19 cents per share in the second quarter of 2024 compared with an adjusted loss of 18 cents per share in the year-ago quarter.
Total revenues were $23.5 million in the second quarter, up 14.6% year over year. Revenues beat the Zacks Consensus Estimate of $17 million.
<h3>Quarter in Detail</h3>
In the second quarter, product sales increased around 42.5% year over year to $6.6 million. Product sales beat our model estimate of $4.6 million.
Non-cash royalty revenues were $16.8 million, up around 6.1% from the year-ago quarter. Non-cash royalty revenues beat our model estimate of $14.8 million.
Research and development (R&amp;D) expenses were $29.7 million, almost flat year over year.
General and administrative (G&amp;A) expenses increased 14.5% year over year to $20.5 million.
Nektar&#39;s stock was down 4.9% in after-hours trading on Aug 8 in response to the mixed results.
Shares of Nektar have skyrocketed 114.1% year to date against the industry&#39;s decline of 5.2%.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/fa/73847.jpg?v=1471947569" /> 
Image Source: Zacks Investment Research
<h3>Pipeline Updates</h3>
Nektar&#39;s lead pipeline candidate is rezpegaldesleukin (rezpeg), which is being developed as a self-administered injection for several autoimmune and inflammatory diseases. NKTR regained full rights to rezpeg from Eli Lily (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lly#NYSE">LLY</a>) in April 2023 and took charge of its clinical development.
Rezpeg was earlier developed in collaboration with Lilly for several autoimmune indications.
Rezpeg is now a wholly owned asset of Nektar and the company owes no royalty payments to LLY.
A phase IIb study is ongoing in patients with moderate-to-severe atopic dermatitis, also called eczema. Initial data from this study is expected in the first half of 2025.
Another phase IIb study is investigating rezpeg for treating patients with severe-to-very severe alopecia areata in March 2024. Top-line data from this study is expected in mid-2025.
<div class="chart_embed">
<h3>Nektar Therapeutics Price, Consensus and EPS Surprise</h3>
<img alt="Nektar Therapeutics Price, Consensus and EPS Surprise" src="https://staticx-tuner.zacks.com/images/charts/41/1723208145.png" style="height:265px; width:574px" title="" />
Nektar Therapeutics price-consensus-eps-surprise-chart | Nektar Therapeutics Quote
</div>
<h3>Zacks Rank &amp; Stocks to Consider</h3>
Nektar currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Exact Sciences Corporation&nbsp;and Entrada Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/trda#NASDAQ">TRDA</a>), each sporting a Zacks Rank #1 (Strong Buy) at present.
In the past 60 days, estimates for Exact Sciences&#39; 2024 loss per share have narrowed from $1.09 to $1.00. Loss per share estimates for 2025 have narrowed from 21 cents to 8 cents. Year to date, shares of EXAS have decreased 22.6%.
EXAS&#39; earnings beat estimates in three of the trailing four quarters while meeting the same on the remaining occasion, the average surprise being 56.19%.
In the past 60 days, estimates for Entrada Therapeutics&#39; 2024 loss per share have narrowed from 14 cents to 13 cents. Loss per share estimates for 2025 have narrowed from $3.44 to $3.21. Year to date, shares of TRDA have lost 4.3%.
TRDA&#39;s earnings beat estimates in two of the trailing four quarters while meeting the same on the remaining two occasions, the average surprise being 42.18%.
<a href="https://www.zacks.com/stock/news/2320141/nektar-s-nktr-q2-earnings-lag-estimates-revenues-top?cid=CS-BENZ-FT-analyst_blog|earnings_article-2320141">To read this article on Zacks.com click here.</a>

Earnings

Earnings Misses

Penny Stocks

Small Cap

Markets

Trading Ideas

TRDA

Nektar's Q2 Earnings Lag Estimates, Revenues Top

Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.21) by 19.05 percent. The company reported quarterly sales of $23.489 million which beat the analyst consensus estimate of $17.545 million by 33.88 percent. This is a 14.59 percent increase over sales of $20.499 million the same period last year.

Earnings Beats

Nektar Therapeutics Q2 2024 GAAP EPS $(0.25) Misses $(0.21) Estimate, Sales $23.489M Beat $17.545M Estimate

– NKTR-0165 Demonstrates Selective Enhancement of Treg Cell Function Through Novel Agonistic Mechanism –
– IND-Enabling Studies Underway for NKTR-0165 with First-in-Human Studies Planned in First Half of 2025 -

Events

Nektar Therapeutics Presents First Preclinical Data On NKTR-0165 For Treatment Of Inflammatory Diseases At EULAR 2024

WIIM

Nektar Therapeutics shares are trading higher after the company reported better-than-expected Q1 financial results.

Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.20) by 5 percent. This is a 73.97 percent increase over losses of $(0.73) per share from the same period last year. The company reported quarterly sales of $21.639 million which beat the analyst consensus estimate of $15.342 million by 41.05 percent. This is a 0.21 percent increase over sales of $21.594 million the same period last year.

Nektar Therapeutics Q1 2024 GAAP EPS $(0.19) Beats $(0.20) Estimate, Sales $21.639M Beat $15.342M Estimate

<h3>Gainers</h3>
<ul>
<li>Clover Health Investments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLOV#NASDAQ">CLOV</a>) shares increased by 14.9% to $0.85 during Tuesday's after-market session. The market value of their outstanding shares is at $421.4 million. The company's, Q1 earnings came out today. </li>
<li>Inogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INGN#NASDAQ">INGN</a>) shares increased by 13.97% to $8.32. The market value of their outstanding shares is at $195.9 million. As per the press release, Q1 earnings came out today. </li>
<li>Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) shares rose 11.92% to $1.69. The market value of their outstanding shares is at $310.3 million. </li>
<li>Agape ATP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATPC#NASDAQ">ATPC</a>) stock increased by 8.33% to $0.26. The company's market cap stands at $20.0 million. </li>
<li>EUDA Health Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EUDA#NASDAQ">EUDA</a>) stock increased by 7.99% to $1.89. The company's market cap stands at $46.5 million. </li>
<li>Atara Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRA#NASDAQ">ATRA</a>) stock rose 7.84% to $0.65. The company's market cap stands at $78.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Treace Medical Concepts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMCI#NASDAQ">TMCI</a>) shares declined by 34.1% to $7.34 during Tuesday's after-market session. The market value of their outstanding shares is at $454.6 million. As per the news, the Q1 earnings report came out today. </li>
<li>Inspire Medical Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INSP#NYSE">INSP</a>) shares fell 15.87% to $206.67. The company's market cap stands at $6.2 billion. As per the press release, Q1 earnings came out today. </li>
<li>Semler Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) stock declined by 15.71% to $23.73. The market value of their outstanding shares is at $166.8 million. As per the press release, Q1 earnings came out today. </li>
<li>Oragenics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/OGEN#AMEX">OGEN</a>) shares fell 14.93% to $1.14. The market value of their outstanding shares is at $5.1 million. </li>
<li>BiomX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PHGE#AMEX">PHGE</a>) stock fell 12.51% to $0.35. The market value of their outstanding shares is at $19.3 million. </li>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) stock declined by 8.28% to $1.22. The company's market cap stands at $13.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ATPC

ATRA

BSGM

CLOV

Euda Health Holdings Limited - Ordinary Shares

EUDA

INGN

INSP

OGEN

PHGE

SMLR

TMCI

12 Health Care Stocks Moving In Tuesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) stock moved upwards by 50.0% to $2.04 during Tuesday's pre-market session. The company's market cap stands at $2.6 million. </li>
<li>GeneDx Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>) shares rose 43.54% to $15.79. The company's market cap stands at $411.3 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>BioRestorative Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRTX#NASDAQ">BRTX</a>) shares moved upwards by 16.93% to $1.45. The company's market cap stands at $9.8 million. </li>
<li>Vaccinex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCNX#NASDAQ">VCNX</a>) shares moved upwards by 15.72% to $6.77. The company's market cap stands at $10.7 million. </li>
<li>Addex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADXN#NASDAQ">ADXN</a>) stock moved upwards by 14.19% to $8.61. The market value of their outstanding shares is at $9.2 million. </li>
<li>Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) stock increased by 9.93% to $109.0. The company's market cap stands at $10.8 billion. The company's, Q1 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>SHL Telemedicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHLT#NASDAQ">SHLT</a>) stock decreased by 10.0% to $5.0 during Tuesday's pre-market session. The company's market cap stands at $81.9 million. </li>
<li>Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) stock declined by 8.87% to $1.33. The market value of their outstanding shares is at $244.3 million. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) shares fell 8.17% to $0.51. The market value of their outstanding shares is at $13.7 million. </li>
<li>GE HealthCare Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEHC#NASDAQ">GEHC</a>) shares declined by 7.81% to $82.0. The market value of their outstanding shares is at $37.4 billion. As per the news, the Q1 earnings report came out today. </li>
<li>Virios Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIRI#NASDAQ">VIRI</a>) stock fell 7.28% to $0.44. The market value of their outstanding shares is at $8.3 million. </li>
<li>180 Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNF#NASDAQ">ATNF</a>) shares decreased by 7.15% to $1.82. The market value of their outstanding shares is at $1.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADXN

ATNF

BRTX

CYCC

GCTK

GEHC

SHLT

VCNX

VIRI

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

To regain compliance with the Minimum Bid Price Requirement, the Company&rsquo;s common stock was required to maintain a closing bid price of $1.00 per share or greater for at least 10 consecutive business days. This requirement was met on April 16, 2024.

Nektar Therapeutics Receives Letter That It Has Regained Compliance With Minimum Bid Price Requirement For Continued Listing On Nasdaq Capital Market - Filing

<h3>Gainers</h3>
<ul>
<li>Rallybio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLYB#NASDAQ">RLYB</a>) shares moved upwards by 70.5% to $2.78 during Thursday's regular session. The company's market cap stands at $105.1 million. </li>
<li>Eliem Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELYM#NASDAQ">ELYM</a>) shares rose 57.3% to $4.2. The market value of their outstanding shares is at $116.4 million. </li>
<li>Candel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CADL#NASDAQ">CADL</a>) shares moved upwards by 40.58% to $7.17. The market value of their outstanding shares is at $210.4 million. </li>
<li>Alpine Immune Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALPN#NASDAQ">ALPN</a>) stock moved upwards by 36.84% to $64.37. The company's market cap stands at $4.2 billion. </li>
<li>Akanda (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAN#NASDAQ">AKAN</a>) shares moved upwards by 29.51% to $0.15. The company's market cap stands at $1.8 million. </li>
<li>Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) shares rose 25.57% to $1.62. The market value of their outstanding shares is at $297.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Aptevo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) shares fell 57.9% to $1.01 during Thursday's regular session. </li>
<li>AVITA Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCEL#NASDAQ">RCEL</a>) shares declined by 30.61% to $10.02. The market value of their outstanding shares is at $257.5 million. </li>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) stock declined by 25.35% to $1.5. The market value of their outstanding shares is at $14.0 million. </li>
<li>MSP Recovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIFW#NASDAQ">LIFW</a>) stock decreased by 20.07% to $1.22. The company's market cap stands at $17.9 million. </li>
<li>Lantern Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRN#NASDAQ">LTRN</a>) stock declined by 15.19% to $6.57. The market value of their outstanding shares is at $70.5 million. </li>
<li>Acorda Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACOR#NASDAQ">ACOR</a>) stock decreased by 14.63% to $0.75. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACOR

AKAN

ALPN

APVO

CADL

ELYM

LIFW

LTRN

RCEL

RLYB

12 Health Care Stocks Moving In Thursday's Intraday Session

Jefferies analyst Roger Song maintains Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) with a Hold and raises the price target from $0.5 to $1.

Jefferies Maintains Hold on Nektar Therapeutics, Raises Price Target to $1

Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>), a biotechnology company developing medicines for the treatment of auto-immune disorders, today announced the initiation of its Phase 2b clinical trial evaluating rezpegaldesleukin in patients with severe to very severe alopecia areata.
Rezpegaldesleukin (REZPEG) is a novel agonistic T regulatory cell biologic that is designed to both dampen the inflammatory response and simultaneously restore immune balance by directly expanding functional T reg cells and engaging multiple immunoregulatory pathways.&nbsp;
"The start of this Phase 2b study is another significant milestone for Nektar as we advance REZPEG, a potentially transformative new mechanism for alopecia areata and other auto-immune disorders," said Mary Tagliaferri, M.D., Chief Medical Officer at Nektar Therapeutics. "Alopecia areata is a disease where a patient's own immune system attacks hair follicles and the resulting hair loss can be devastating for patients.&nbsp; Current treatments available have high relapse rates and carry potential safety challenges. As a result, there is a high unmet need for durable and well-tolerated treatment options that target the underlying dysfunction of the immune system in these patients. We believe there's an opportunity for REZPEG to emerge as a novel biologic mechanism for alopecia patients and we look forward to our topline data from this study expected in the first half of 2025."
Nektar's global, randomized, double-blind, placebo-controlled, dose-ranging Phase 2b study will investigate the efficacy and safety of REZPEG in 84 participants with severe to very severe alopecia areata over a 36-week induction treatment period. The induction treatment period will compare two different dosing regimens of REZPEG against placebo. Participants will be followed for an additional 24 weeks after the end of the treatment period to evaluate durability. Initial results from the study are anticipated in the first half of 2025.
The primary efficacy endpoint will evaluate mean percent improvement in the Severity of Alopecia Tool (SALT) at week 36. Secondary endpoints include proportion of participants with greater than or equal to 50% reduction in SALT at week 36 and other assessed timepoints and mean percent improvement in SALT at other assessed timepoints.

Nektar Therapeutics Announces Initiation Of Phase 2b Clinical Study Evaluating Rezpegaldesleukin In Patients With Severe To Very Severe Alopecia Areata

Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.23) by 4.35 percent. The company reported quarterly sales of $23.89 million which beat the analyst consensus estimate of $18.05 million by 32.29 percent. This is a 8.45 percent increase over sales of $22.02 million the same period last year.

Nektar Therapeutics Q4 2023 GAAP EPS $(0.22) Beats $(0.23) Estimate, Sales $23.89M Beat $18.05M Estimate

Shares of Bitdeer Technologies Group (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/btdr#NASDAQ">BTDR</a>) rose sharply during Monday&rsquo;s session after the company reported preliminary fourth-quarter financial results, announced the successful testing of its SEAL01 Bitcoin mining chip and amid overall strength in the price of Bitcoin.
Bitdeer Technologies Group shares jumped 10.2% to $7.45 on Monday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>BitFuFu Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fufu#NASDAQ">FUFU</a>) shares jumped 107% to $13.20 amid volatility following the company&#39;s recent business combination with Arisz Acquisition Corp and listing on the Nasdaq.</li>
<li>Quoin Pharmaceuticals, Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/qnrx#NASDAQ">QNRX</a>) climbed 89% to $5.31 after the company announced FDA clearance to recruit teen subjects into both of its ongoing Netherton Syndrome clinical studies.</li>
<li>Renalytix Plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rnlx#NASDAQ">RNLX</a>) gained 52.8% to $1.5890 after the company announced that it received an unsolicited approach from a publicly listed strategic diagnostics company.</li>
<li>Phunware, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/phun#NASDAQ">PHUN</a>) climbed 42.7% to $10.11. Phunware is expected to report fourth-quarter results on March 12, 2024.</li>
<li>Ainos, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aimd#NASDAQ">AIMD</a>) gained 39.4% to $1.4650.</li>
<li>Jaguar Health, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jagx#NASDAQ">JAGX</a>) shares climbed 38.2% to $0.1223 after surging 50% on Friday.</li>
<li>Cardiff Oncology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crdf#NASDAQ">CRDF</a>) rose 31.6% to $3.83 after the company reported better-than-expected fourth-quarter financial results, provided a clinical update on the Phase 2 randomized second-line ONSEMBLE trial in patients with RAS-mutated mCRC and announced the first patient was dosed in the randomized first-line RAS-mutated mCRC trial.</li>
<li>The E.W. Scripps Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ssp#NASDAQ">SSP</a>) gained 31.3% to $4.94. E.W. Scripps Director Charles L. Barmonde acquired a total of 10,500 shares an average price of $4.28.</li>
<li>Helius Medical Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hsdt#NASDAQ">HSDT</a>) climbed 30% to $5.91. Helius Medical Technologies announced it secured HCPCS codes for portable neuromodulation stimulator mouthpiece and controller.</li>
<li>Kineta, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ka#NASDAQ">KA</a>) gained 27% to $1.14. Kineta recently announced a restructuring and the exploration of strategic alternatives.</li>
<li>BigBear.ai Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bbai#NYSE">BBAI</a>) rose 25% to $4.3472.</li>
<li>Critical Metals Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crml#NASDAQ">CRML</a>) gained 24.4% to $12.44.</li>
<li>Ocean Biomedical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ocea#NASDAQ">OCEA</a>) gained 22% to $2.44.</li>
<li>Reliance Global Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/reli#NASDAQ">RELI</a>) rose 21.7% to $0.6299 after gaining 11% on Friday.</li>
<li>Akero Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/akro#NASDAQ">AKRO</a>) climbed 21.1% to $33.69 after gaining 3% on Friday.</li>
<li>89bio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/etnb#NASDAQ">ETNB</a>) gained 20.3% to $15.18.</li>
<li>Nektar Therapeutics (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nktr#NASDAQ">NKTR</a>) gained 19.4% to $0.9315. Nektar Therapeutics announced a $30 million private placement financing with TCGX.</li>
<li>Super Micro Computer, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smci#NASDAQ">SMCI</a>) shares gained 18.9% to $1,076.45. Super Micro Computer will join the S&amp;P 500 Index, effective March 18, S&amp;P Dow Jones Indices, a division of S&amp;P Global, said in a release.</li>
<li>MicroStrategy Incorporated (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mstr#NASDAQ">MSTR</a>) gained 17.8% to $1,271.51 amid strength in Bitcoin.</li>
<li>Macy&#39;s, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/m#NYSE">M</a>) rose 16.3% to $20.95 after Arkhouse and Brigade Capital increased their offer to acquire Macy&#39;s to $24 per share.</li>
<li>Renovaro Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/renb#NASDAQ">RENB</a>) gained 14.3% to $2.64.</li>
<li>Digital World Acquisition Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dwac#NASDAQ">DWAC</a>) gained 13.4% to $44.18 after falling over 5% on Friday.</li>
<li>MGE Energy, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mgee#NASDAQ">MGEE</a>) rose 12% to $70.75. MGE Energy will replace iRobot in the S&amp;P SmallCap 600.</li>
<li>BGC Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bgc#NASDAQ">BGC</a>) gained 11.8% to $7.93. BGC Group is set to join S&amp;P SmallCap 600.</li>
<li>Jin Medical International Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/zjyl#NASDAQ">ZJYL</a>) climbed 11.6% to $7.10.</li>
<li>H&amp;R Block, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hrb#NYSE">HRB</a>) gained 8.9% to $52.08.</li>
<li>Aadi Bioscience, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aadi#NASDAQ">AADI</a>) shares surged 8.8% to $2.0899 after the company announced publication of long-term efficacy and safety data further supporting FYARRO&reg; for the treatment of malignant PEComa.</li>
<li>MSP Recovery, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lifw#NASDAQ">LIFW</a>) shares rose 7.7% to $1.11. LifeWallet announced a comprehensive settlement with 28 affiliated property and casualty insurers, benefiting LifeWallet&rsquo;s <a href="https://www.benzinga.com/money/best-medicare-advantage-plans/">medicare</a> clients across the U.S.</li>
<li>Coinbase Global, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/coin#NASDAQ">COIN</a>) climbed 7.5% to $221.11 amid a rise in the price of Bitcoin.</li>
<li>Box, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/box#NYSE">BOX</a>) gained 6.6% to $28.30. Box will replace Forrester Research Inc in the S&amp;P SmallCap 600.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>BioVie Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bivi#NASDAQ">BIVI</a>) fell 42.7% to $1.0830 after the company reported pricing of public offering.</li>
<li>JOANN Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/joan#NASDAQ">JOAN</a>) fell 38.7% to $ .3102&nbsp;following a report suggesting the company may file for bankruptcy soon.</li>
<li>Astra Space, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/astr#NASDAQ">ASTR</a>) dipped 35% to $0.8598.</li>
<li>BioCardia, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bcda#NASDAQ">BCDA</a>) fell 23.3% to $0.4449 after reporting interim results from Phase III CardiAMP cell therapy heart failure trial.</li>
<li>MMTec, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mtc#NASDAQ">MTC</a>) declined 21.8% to $2.00.</li>
<li>Vivani Medical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vani#NASDAQ">VANI</a>) declined 21.7% to $2.4199. Vivani Medical recently announced the pricing of a $15 million registered direct offering of common stock and warrants.</li>
<li>Interactive Strength Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/trnr#NASDAQ">TRNR</a>) tumbled 19.8% to $0.40. Interactive Strength recently announced it has entered into an exclusive worldwide distribution agreement with WOODWAY to sell and distribute CLMBR.</li>
<li>Infobird Co., Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ifbd#NASDAQ">IFBD</a>) dipped 19.3% to $5.03</li>
<li>Minim, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/minm#NASDAQ">MINM</a>) fell 18.4% to $4.7395 after jumping 35% on Friday.</li>
<li>Avidity Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rna#NASDAQ">RNA</a>) fell 16.6% to $16.78. Avidity Biosciences announced new long-term AOC 1001 data from the Marina-OLE trial showing reversal of disease progression in Myotonic Dystrophy Type 1 patients across multiple endpoints.</li>
<li>Playtika Holding Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pltk#NASDAQ">PLTK</a>) fell 14.8% to $6.44</li>
<li>Aptevo Therapeutics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/apvo#NASDAQ">APVO</a>) declined 14.7% to $0.1399.</li>
<li>J-Long Group Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jl#NASDAQ">JL</a>) shares dipped 14.3% to $1.98 after jumping over 15% on Friday. J-Long Group recently declared a special cash dividend in aggregate amount of $6 million.</li>
<li>Sunshine Biopharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sbfm#NASDAQ">SBFM</a>) fell 14.3% to $0.0474. Sunshine Biopharma, last month, announced closing of $10.0 million underwritten public offering.</li>
<li>New York Community Bancorp, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nycb#NASDAQ">NYCB</a>) fell 13.6% to $3.0650 after the company announced that it identified material weaknesses in its internal controls related to internal loan review, that resulted from ineffective oversight, risk assessment and monitoring activities.</li>
<li>Spirit Airlines, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/save#NYSE">SAVE</a>) fell 12.1% to $5.68 after the company announced the termination of its merger agreement with JetBlue.</li>
<li>Sabre Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sabr#NASDAQ">SABR</a>) fell 11.6% to $2.3050. Sabre announced exchange of $150 million of existing 4.000% exchangeable senior notes due 2025 for exchangeable senior notes due 2026.</li>
<li>Li Auto Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/li#NASDAQ">LI</a>) fell 11.6% to $38.49. B of A Securities analyst Ming Hsun Lee maintained Li Auto with a Buy and raised the price target from $57 to $60.</li>
<li>Revance Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rvnc#NASDAQ">RVNC</a>) fell 11.2% to $6.20. Revance announced pricing of $100 million public offering of 16 million shares of common stock at a price of $6.25 per share.</li>
<li>Beyond Meat, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bynd#NASDAQ">BYND</a>) dipped 11.3% to $8.67 after the company announced that it was unable to file its annual report due to technical difficulties in assembling the submission for filing. Also, the company said it anticipates it will seek to raise additional capital in 2024.</li>
<li>Caledonia Mining Corporation Plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cmcl#NASDAQ">CMCL</a>) shares tumbled 9.6% to $9.29 after the company issued a trading update for the year ended Dec. 31, 2023.</li>
<li>Hertz Global Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/htz#NYSE">HTZ</a>) fell 7.2% to $7.26.</li>
<li>NIO Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nio#NYSE">NIO</a>) fell 6.9% to $5.38.</li>
</ul>
&nbsp;
Now Read This: <a href="	https://www.benzinga.com/trading-ideas/long-ideas/24/03/37454953/charles-colvard-and-3-other-penny-stocks-insiders-are-buying"> Charles &amp; Colvard And 3 Other Penny Stocks Insiders Are Buying </a>

Intraday Update

AADI

AIMD

AKRO

ASTR

BBAI

BCDA

BIVI

BTDR

BYND

CMCL

COIN

CRDF

CRML

DWAC

ETNB

FUFU

HSDT

IFBD

JAGX

JOAN

MGEE

MINM

MSTR

NYCB

OCEA

PHUN

PLTK

QNRX

RELI

RENB

RNLX

RVNC

SABR

SAVE

SBFM

SMCI

TRNR

VANI

ZJYL

Why Bitdeer Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Nektar Therapeutics shares are trading higher after the company announced $30 million in private placement financing with TCGX.

Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>), a biotechnology company developing medicines for the treatment of auto-immune disorders, today announced that it has entered into a securities purchase agreement with TCGX, an institutional accredited investor, to sell securities in a private placement financing (the "PIPE") for gross proceeds of $30 million, before deducting expenses.
In the PIPE, Nektar is selling 25 million shares of its common stock, in the form of a pre-funded warrant, at a price of $1.20 per share, representing a premium of approximately 80% to Nektar's 30-day volume-weighted average price. The pre-funded warrant will have an exercise price of $0.0001 per share and will not expire.
The PIPE is expected to close on or before March 6, 2024, subject to customary closing conditions. Nektar has agreed to submit a registration statement filing for the underlying Common Stock no later than 90 days after the closing.
"We are pleased to bring on TCGX as a new high-quality, long-term investor in Nektar as we advance rezpegaldesleukin through our Phase 2b studies in atopic dermatitis and alopecia areata," said Howard Robin, President and Chief Executive Officer of Nektar Therapeutics. "We are on track to report topline data from these studies in the first half of 2025, which will represent significant inflection points for Nektar. Today's financing further bolsters our financial position and extends the company's cash runway well into the third quarter of 2026."
Rezpegaldesleukin is a novel agonistic T regulatory cell biologic that is designed to both dampen the inflammatory response and simultaneously restore immune balance by directly expanding functional T reg cells and engaging multiple immunoregulatory pathways.&nbsp;
The private placement is exempt from the registration requirements of the Securities Act pursuant to the exemption for transactions by an issuer not involving any public offering under Section 4(a)(2) of the Securities Act of 1933, as amended and Rule 506 of Regulation D of the Securities Act of 1933, as amended and in reliance on similar exemptions under applicable state laws.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Offerings

Nektar Therapeutics Announces $30M Private Placement Financing With TCGX; Nektar Is Selling 25M Shares Of Its Common Stock, In The Form Of A Pre-Funded Warrant, At A Price Of $1.20 Per Share

<h3>Companies Reporting Before The Bell</h3>
&bull; Sohu.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOHU#NASDAQ">SOHU</a>) is estimated to report earnings for its fourth quarter.
&bull; Avadel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVDL#NASDAQ">AVDL</a>) is projected to report quarterly loss at $0.29 per share on revenue of $18.11 million.
&bull; LENSAR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNSR#NASDAQ">LNSR</a>) is expected to report quarterly loss at $0.22 per share on revenue of $12.00 million.
&bull; Sea (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SE#NYSE">SE</a>) is projected to report quarterly loss at $0.27 per share on revenue of $3.53 billion.
&bull; Global Ship Lease (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSL#NYSE">GSL</a>) is estimated to report quarterly earnings at $2.35 per share on revenue of $172.02 million.
&bull; Modiv Industrial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDV#NYSE">MDV</a>) is likely to report earnings for its fourth quarter.
&bull; GEO Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEO#NYSE">GEO</a>) is estimated to report earnings for its fourth quarter.
<h3>Companies Reporting After The Bell</h3>
&bull; Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) is estimated to report quarterly loss at $0.21 per share on revenue of $18.05 million.
&bull; Ekso Bionics Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EKSO#NASDAQ">EKSO</a>) is estimated to report quarterly loss at $0.11 per share on revenue of $4.77 million.
&bull; ContextLogic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WISH#NASDAQ">WISH</a>) is likely to report quarterly loss at $2.66 per share on revenue of $53.06 million.
&bull; Stellus Cap Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCM#NYSE">SCM</a>) is expected to report quarterly earnings at $0.45 per share on revenue of $27.41 million.
&bull; Crawford &amp; Company Common Stock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRD#NYSE">CRD</a>) is expected to report quarterly earnings at $0.20 per share on revenue of $317.48 million.
&bull; Eos Energy Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOSE#NASDAQ">EOSE</a>) is likely to report quarterly loss at $0.25 per share on revenue of $9.00 million.
&bull; Southland Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SLND#AMEX">SLND</a>) is expected to report quarterly earnings at $0.02 per share on revenue of $274.41 million.
&bull; Commercial Vehicle Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVGI#NASDAQ">CVGI</a>) is likely to report quarterly earnings at $0.14 per share on revenue of $226.24 million.
&bull; Paymentus Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAY#NYSE">PAY</a>) is estimated to report quarterly earnings at $0.07 per share on revenue of $157.42 million.
&bull; Northwest Pipe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWPX#NASDAQ">NWPX</a>) is likely to report quarterly earnings at $0.42 per share on revenue of $107.35 million.
&bull; Crescent Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRGY#NYSE">CRGY</a>) is estimated to report quarterly earnings at $0.15 per share on revenue of $607.02 million.
&bull; Stitch Fix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFIX#NASDAQ">SFIX</a>) is estimated to report quarterly loss at $0.20 per share on revenue of $330.85 million.
&bull; Stereotaxis (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/STXS#AMEX">STXS</a>) is expected to report quarterly loss at $0.07 per share on revenue of $7.70 million.
&bull; SEMrush Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEMR#NYSE">SEMR</a>) is estimated to report quarterly earnings at $0.03 per share on revenue of $83.11 million.
&bull; Akoya Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKYA#NASDAQ">AKYA</a>) is expected to report quarterly loss at $0.27 per share on revenue of $25.89 million.
&bull; ThredUp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TDUP#NASDAQ">TDUP</a>) is likely to report quarterly loss at $0.13 per share on revenue of $80.33 million.
&bull; AeroVironment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVAV#NASDAQ">AVAV</a>) is estimated to report quarterly earnings at $0.33 per share on revenue of $170.62 million.
&bull; Cara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARA#NASDAQ">CARA</a>) is estimated to report quarterly loss at $0.41 per share on revenue of $9.42 million.
&bull; GitLab (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTLB#NASDAQ">GTLB</a>) is expected to report quarterly earnings at $0.08 per share on revenue of $158.21 million.
&bull; Viant Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSP#NASDAQ">DSP</a>) is estimated to report quarterly loss at $0.03 per share on revenue of $65.92 million.
&bull; Vicarious Surgical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBOT#NYSE">RBOT</a>) is expected to report earnings for its fourth quarter.
&bull; Innovate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VATE#NYSE">VATE</a>) is likely to report earnings for its fourth quarter.
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

AKYA

AVAV

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

CARA

CRGY

CVGI

EKSO

EOSE

GTLB

LNSR

NWPX

RBOT

SEMR

SFIX

SLND

SOHU

STXS

TDUP

VATE

WISH

Earnings Scheduled For March 4, 2024

Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) is set to give its latest quarterly earnings report on Monday, 2024-03-04. Here's what investors need to know before the announcement.
Analysts estimate that Nektar Therapeutics will report an earnings per share (EPS) of $-0.21. 
Nektar Therapeutics bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
Last quarter the company beat EPS by $0.01, which was followed by a 8.76% drop in the share price the next day.
Here's a look at Nektar Therapeutics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.20</td>
<td>-0.28</td>
<td>-0.25</td>
<td>-0.45</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.19</td>
<td>-0.27</td>
<td>-0.25</td>
<td>-0.32</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-9.0%</td>
<td>-9.0%</td>
<td>-2.0%</td>
<td>9.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1709308837_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Nektar Therapeutics were trading at $0.71 as of February 29. Over the last 52-week period, shares are down 49.2%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/NKTR/earnings">To track all earnings releases for Nektar Therapeutics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Nektar Therapeutics Earnings Preview

Nektar files to sell 25M shares of common stock for holders

Russell 3000: Inovio, Ocugen among healthcare additions; Assertio, Ginkgo Bioworks among deletions

Nektar, Verastem among healthcare additions in Russell Microcap; Assertio, Sangamo removed

Nektar Therapeutics Likely To Drift And Wobble Ahead Of Key Phase II Data In 2025

In a report released today, Jay Olson from Oppenheimer maintained a Hold rating on Nektar Therapeutics (NKTR – Research Report). The company's shar...

Oppenheimer Reaffirms Their Hold Rating on Nektar Therapeutics (NKTR)

Nektar Therapeutics Non-GAAP EPS of -$0.19, revenue of $23.49M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Nektar Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/nktr-stock-quote/">NKTR</a>) just reported results for the second quarter of 2024.<ul><li>Nektar Therapeutics reported earnings per share of -25 cents. This was below the analyst estimate for EPS of -20 cents.</li><li>The company reported revenue of $23.49 million.</li><li>This was 33.92% better than the analyst estimate for revenue of $17.54 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/nktr-stock-earnings-nektar-therapeutics-for-q2-of-2024/">NKTR Stock Earnings: Nektar Therapeutics Misses EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

NKTR Stock Earnings: Nektar Therapeutics Misses EPS, Beats Revenue for Q2 2024

Nektar Therapeutics (NKTR) Q2 2024 Earnings Call Transcript

Nektar rises 11% as BTIG initiates buy rating on autoimmune disorders asset

Nektar sees promising phase 1 results of NKTR-255 in B-cell lymphoblastic leukemia

ABBV

AMGN

ASRT

BFLY

MNMD

OCGN

REGN

SGMO

TXMD

VSTM

Press Releases

Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference

Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial Markets

Nektar Therapeutics Reports First Quarter 2024 Financial Results

Nektar Management to Present at Upcoming Investor Conferences

Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024

Nektar to Announce Financial Results for the Second Quarter 2024 on Thursday, August 8, 2024, After Close of U.S.-Based Financial Markets

Nektar Therapeutics Reports Second Quarter 2024 Financial Results

Nektar Therapeutics Announces Multiple Presentations for Rezpegaldesleukin at EADV 2024

Nektar Announces Publication in Blood of Phase 1 Data for Novel IL-15 Agonist NKTR-255 in Combination with Autologous CD19-22 CAR-T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia

Amylyx Pharmaceuticals, Inc. - Common Stock

Amylyx Pharma

Alto Neuroscience

Aquestive Therapeutics, Inc. - Common Stock

Aquestive Therapeutics

Atea Pharmaceuticals, Inc. - common stock

Atea Pharmaceuticals

Biote

Context Therapeutics

Contineum Therapeutics, Inc. - Common stock

Contineum Therapeutics

Esperion Therapeutics, Inc. - Common Stock

Esperion Therapeutics

Eton Pharmaceuticals, Inc. - Common Stock

Eton Pharmaceuticals

Fulcrum Therapeutics, Inc. - Common Stock

Fulcrum Therapeutics

Comments

Nektar Therapeutics

Notizie

Ultime notizie per Nektar Therapeutics (NASDAQ:NKTR) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO